AI Unlocks Marine-Derived RIPK1 Inhibitors
Advances in computational drug discovery are reshaping how we identify new therapeutics. A recent study in In Silico Pharmacology (2026) demonstrates this transformation by uncovering promising inhibitors of Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)—a critical regulator of necroptosis linked to neurodegenerative diseases, inflammation, and cancer.
Despite its importance, RIPK1 remains an underexploited drug target, with no approved therapies currently available. This study addresses that gap using a powerful combination of machine learning, virtual screening, and molecular simulations.
A Smarter Discovery Pipeline
The researchers developed a Gradient Boosting machine learning model trained on curated ChEMBL data. The model showed excellent predictive performance (accuracy and F1-score of 0.97; ROC-AUC of 0.99), enabling efficient identification of potential inhibitors.
Using this model, they screened 5,472 compounds from the Comprehensive Marine Natural Product Database (CMNPD). Marine natural products are especially valuable due to their structural diversity and unique bioactivity.
Following screening, candidates were refined through:
- ADMET filtering (to assess drug-likeness and safety)
- Molecular docking (to evaluate binding affinity to RIPK1)
Promising Candidates Identified
Four marine-derived compounds stood out:
- CMNPD23788
- CMNPD14579
- CMNPD15831
- CMNPD26709
These compounds demonstrated strong binding affinities (−10.3 to −9.9 kcal/mol), comparable to known RIPK1 inhibitors such as L8D.
Stability Confirmed by Molecular Simulations
To validate these findings, the study employed 200 ns molecular dynamics simulations alongside MM-PBSA binding free energy calculations. The results confirmed that all four compounds form stable complexes with RIPK1, reinforcing their potential as viable drug candidates.
Why This Matters
This research highlights three key insights:
- AI accelerates discovery by rapidly narrowing down candidate compounds.
- Marine biodiversity offers untapped chemical space for drug development.
- Integrated computational pipelines—combining ML, docking, and MD simulations—provide robust early-stage validation.
What Comes Next
While the results are promising, they remain computational. Experimental validation is essential, including biochemical assays and disease model studies, particularly in necroptosis-related neurodegeneration.
Conclusion
By combining artificial intelligence with molecular simulation, this study identifies four novel RIPK1 inhibitor candidates from marine natural products. It underscores the growing role of computational pharmacology in accelerating drug discovery and opens new avenues for targeting diseases driven by necroptosis.
https://link.springer.com/article/10.1007/s40203-026-00586-8
